Key result
Antiretroviral therapy reduces hs-cTnT by ~16% in newly diagnosed people living with HIV.
Why the study?
The presence and evolution of subclinical myocardial injury, remodeling, and fibrosis in newly diagnosed ART-naïve PLWH and the impact of ART on cardiac biomarkers and tissue abnormalities remain unclear.
Does antiretroviral therapy improve cardiac biomarkers of myocardial injury and remodeling in newly diagnosed people living with HIV?
Cohort (n=95)
Does antiretroviral therapy improve cardiac biomarkers of myocardial injury and remodeling in newly diagnosed people living with HIV?
Initiation of antiretroviral therapy in newly diagnosed HIV patients is associated with significant reductions in biomarkers of subclinical myocardial injury and remodeling, which correlate with CMR tissue characterization.
Answers are grounded in this paper and cite their sources.
Cardiac biomarkers may flag subclinical myocardial injury in early HIV; leaves open their utility for post-ART monitoring or outcome prediction.
Aims Biochemical markers are fundamental in cardiac evaluation, and various novel assays have recently been discovered. We prospectively evaluated the hearts of newly diagnosed people living with human immunodeficiency virus (PLWH) using cardiac biomarkers, compared them with human immunodeficiency virus (HIV)-uninfected controls, and correlated our prospective findings with cardiovascular magnetic resonance imaging (CMR). Methods and results Newly diagnosed, antiretroviral therapy (ART)-naïve PLWH were recruited along with HIV-uninfected, age-matched, and sex-matched controls. All participants underwent measurement of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-B-type natriuretic peptide (NT-proBNP), soluble ST2 (sST2), and galectin-3, as well as a CMR study with multiparametric mapping. The HIV group started ART and was re-evaluated 9 months later. The cardiac biomarkers and their correlation with CMR parameters were evaluated in and between groups. Compared with controls (n = 22), hs-cTnT (4.0 vs. 5.1 ng/L; P = 0.004), NT-proBNP (23.2 vs. 40.8 ng/L; P = 0.02), and galectin-3 (6.8 vs. 9.0 ng/mL; P = 0.002) were all significantly higher in the ART-naïve group (n = 73). After 9 months of ART, hs-cTnT (5.1 vs. 4.3 ng/L; P = 0.02) and NT-proBNP (40.8 vs. 28.5 ng/L; P = 0.03) both decreased significantly and a trend of decrease was seen in sST2 (16.5 vs. 14.8 ng/L; P = 0.08). Galectin-3 did not demonstrate decrease over time (9.0 vs. 8.8 ng/mL; P = 0.6). The cardiac biomarkers that showed the best correlation with CMR measurements native T1, T2, and extracellular volume were NT-proBNP (rs ≥ 0.4, P < 0.001) and galectin-3 (rs ≥ 0.3, P < 0.01). Conclusions Our cardiac biomarker data support the presence of subclinical myocardial injury, remodelling, and fibrosis at HIV diagnosis, and ART had a positive influence on these blood markers. It remains unclear if the underlying pathological processes were fully addressed by ART. The ability of cardiac biomarkers to detect and track tissue abnormalities diagnosed with CMR showed promise. With additional research, this could lead to improvements in screening and monitoring myocardial abnormalities, even in CMR-limited settings.
No takes yet. Share an insight, caveat, or question.
Robbertse et al. (2023) conducted a cohort in HIV (n=95). Antiretroviral therapy (ART) vs. Baseline (ART-naïve) was evaluated on High-sensitivity cardiac troponin T (hs-cTnT) levels (p=0.02). After 9 months of antiretroviral therapy, hs-cTnT decreased from 5.1 to 4.3 ng/L and NT-proBNP decreased from 40.8 to 28.5 ng/L in newly diagnosed people living with HIV.
Synapse has enriched 10 related papers. Consider them for comparative context: